Cabergoline monotherapy in the long-term treatment of Cushing's disease
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Background: Cabergoline is a long-acting dopamine receptor agonist used to treat prolactinomas. Identification of D 2 receptors in corticotroph tumors led to clinical trials of cabergoline therapy in limited cases of Nelson's syndrome, ectopic ACTH-secreting tumors, and recently Cushing's disease (CD). Objective: To evaluate the long-term efficacy of cabergoline monotherapy in patients with CD. Methods: Retrospective analysis of non-randomized clinical therapy with cabergoline in 30 patients with CD treated in academic centers of Buenos Aires and Montreal. Cabergoline was initiated at 0.5–1.0 mg/week and adjusted up to a maximal dose of 6 mg/week based on urinary free cortisol (UFC) levels. Complete response to cabergoline was defined as a sustained normalization of UFC with at least two normal values measured at 1–3 months interval; partial response was defined as a decrease of UFC to <125% of the upper limit of normal, and treatment failure as UFC ≥125% of it. Results: Within 3–6 months, complete response was achieved in 11 patients (36.6%) and partial response in 4 patients (13.3%). After long-term therapy, nine patients (30%) remain with a complete response after a mean of 37 months (range from 12 to 60 months) with a mean dose of 2.1 mg/week of cabergoline. Two patients escaped after 2 and 5 years of complete response, but one patient transiently renormalized UFC after an increase in cabergoline dosage. No long-term response was maintained in four initial partial responders. Conclusions: Cabergoline monotherapy can provide an effective long-term medical therapy for selected patients with CD, but requires close follow-up for dose adjustments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In clinical trials, the efficacy of steroidogenesis inhibitors and pituitary-directed therapies in patients with CS was primarily evaluated by the normalization of cortisol secretion per UFC (129-137).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [137]
In the citing paper
“The restoration of cortisol circadian rhythm following medical therapy has not been investigated or established for most medications used to treat CS, and it is not routinely measured to determine treatment response (129-137).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [137]
In the citing paper
“Mean UFC is routinely used in clinical practice and research to monitor disease control and treatment response in patients with CS treated with medical therapy (129-137).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [137]
Citations
Cites
Diagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362 · cited 3×
“The resulting hypercortisolism in CD is responsible for important cardiovascular, metabolic and other morbidities (1).”
BackgroundInfluentialSelf-citationValvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884
Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement
Biller, B. M. K., Grossman, A. B., Stewart, P. M., Melmed, S., Bertagna, X., Bertherat, J., Buchfelder, M., Colao, A., Hermus, A. R., Hofland, L. J., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2734 · Cited by 853
Self-citationDopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 718
Dopamine Agonists and Pituitary Tumor Shrinkage
BEVAN, J. S., WEBSTER, J., Burke, C. W., & Scanlon, M. F. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-2-220 · Cited by 469
Pivonello, R., De Martino, M. C., Cappabianca, P., De Leo, M., Faggiano, A., Lombardi, G., Hofland, L. J., Lamberts, S. W. J., & Colao, A. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1533 · Cited by 328
Boscaro, M., Ludlam, W. H., Atkinson, B., Glusman, J. E., Petersenn, S., Reincke, M., Snyder, P., Tabarin, A., Biller, B. M. K., Findling, J., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1008 · Cited by 279
Dopamine Receptor Expression and Function in Corticotroph Pituitary Tumors
Pivonello, R., Ferone, D., de Herder, W. W., Kros, J. M., Del Basso De Caro, M. L., Arvigo, M., Annunziato, L., Lombardi, G., Colao, A., Hofland, L. J., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030837 · Cited by 271
Atkinson, A. B., Kennedy, A., Wiggam, M. I., McCance, D. R., & Sheridan, B. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02380.x · Cited by 263
Pasireotide Alone or with Cabergoline and Ketoconazole in Cushing's Disease
Feelders, R. A., de Bruin, C., Pereira, A. M., Romijn, J. A., Netea-Maier, R. T., Hermus, A. R., Zelissen, P. M., van Heerebeek, R., de Jong, F. H., van der Lely, A.-J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1000094 · Cited by 262
Bromocriptine: a novel approach to the treatment of type 2 diabetes.
Pijl, H., Ohashi, S., Matsuda, M., Miyazaki, Y., Mahankali, A., Kumar, V, Pipek, R., Iozzo, P., Lancaster, J. L., Cincotta, A. H., et al. (2000) · Diabetes Care · doi:10.2337/diacare.23.8.1154 · Cited by 238
Assié, G., Bahurel, H., Coste, J., Silvera, S., Kujas, M., Dugué, M.-A., Karray, F., Dousset, B., Bertherat, J., Legmann, P., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1328 · Cited by 230
Repeat transsphenoidal surgery for Cushing's disease
Friedman, R. B., Oldfield, E. H., Nieman, L. K., Chrousos, G. P., Doppman, J. L., Cutler, G. B., & Loriaux, D. L. (1989) · Journal of Neurosurgery · doi:10.3171/jns.1989.71.4.0520 · Cited by 211
The Medical Treatment of Cushing's Syndrome
MILLER, J. W., & CRAPO, L. (1993) · Endocrine Reviews · doi:10.1210/edrv-14-4-443 · Cited by 202
Medical Therapy of Cushing's Disease
Nieman, L. K. (2002) · Pituitary · doi:10.1023/a:1022308429992 · Cited by 185
Vilar, L., Naves, L. A., Azevedo, M. F., Arruda, M. J., Arahata, C. M., Silva, L. M. E., Agra, R., Pontes, L., Montenegro, L., Albuquerque, J. L., et al. (2009) · Pituitary · doi:10.1007/s11102-009-0209-8 · Cited by 154
Dopamine receptor agonists for treating prolactinomas
Colao, A., Somma, C. D., Lombardi, G., Pivonello, R., & Sarno, A. D. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.6.787 · Cited by 141
Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma
Benveniste, R. J., King, W. A., Walsh, J., Lee, J. S., Delman, B. N., & Post, K. D. (2005) · Journal of Neurosurgery · doi:10.3171/jns.2005.102.6.1004 · Cited by 134
LAMBERTS, S. W. J., KLIJN, J. G. M., DE QUIJADA, M., TIMMERMANS, H. A. T., UITTERLINDEN, P., DE JONG, F. H., & BIRKENHAGER, J. C. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-51-2-307 · Cited by 128
Coexpression of Dopamine and Somatostatin Receptor Subtypes in Corticotroph Adenomas
de Bruin, C., Pereira, A. M., Feelders, R. A., Romijn, J. A., Roelfsema, F., Sprij-Mooij, D. M., van Aken, M. O., van der Lelij, A.-J., de Herder, W. W., Lamberts, S. W. J., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2101 · Cited by 124
De Tommasi, C., Vance, M. L., Okonkwo, D. O., Diallo, A., & Laws, E. R. (2005) · Journal of Neurosurgery · doi:10.3171/jns.2005.103.5.0825 · Cited by 81
Colao, A., Lombardi, G., & Annunziato, L. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.3.555 · Cited by 75
Casulari, L. A., Naves, L. A., Mello, P. A., Pereira Neto, A., & Papadia, C. (2004) · Hormone Research in Paediatrics · doi:10.1159/000082235 · Cited by 71
Dopamine Receptor Expression and Function in Corticotroph Ectopic Tumors
Pivonello, R., Ferone, D., de Herder, W. W., Faggiano, A., Bodei, L., de Krijger, R. R., Lombardi, G., Colao, A., Lamberts, S. W. J., & Hofland, L. J. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0728 · Cited by 68
Dopamine: a role in the pathogenesis and treatment of hypertension
Murphy, M. B. (2000) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1000987 · Cited by 66
Complete remission of Nelson’s syndrome after 1-year treatment with cabergoline
Pivonello, R., Faggiano, A., Salle, F. D., Filippella, M., Lombardi, G., & Colao, A. (1999) · Journal of Endocrinological Investigation · doi:10.1007/bf03343660 · Cited by 66
Cushing’s disease in dogs: Cabergoline treatment
Castillo, V. A., Gómez, N. V., Lalía, J., Blatter, M. F. C., & García, J. D. (2007) · Research in Veterinary Science · doi:10.1016/j.rvsc.2007.08.009 · Cited by 60
Surgical Treatment of Recurrent Cushing's Disease
Hofmann, B. M., Hlavac, M., Kreutzer, J., Grabenbauer, G., & Fahlbusch, R. (2006) · Neurosurgery · doi:10.1227/01.neu.0000215945.26764.92 · Cited by 56
BROMOCRIPTINE IN NELSON'S SYNDROME AND CUSHING'S DISEASE
Lamberts, S. W. J. (1976) · The Lancet · doi:10.1016/s0140-6736(76)90656-5 · Cited by 55
de Bruin, C., Hanson, J., Meij, B. P., Kooistra, H. S., Waaijers, A. M., Uitterlinden, P., Lamberts, S. W. J., & Hofland, L. J. (2008) · Endocrinology · doi:10.1210/en.2008-0244 · Cited by 39
Beneficial Effects of High Daily Dose Bromocriptine Treatment in Cushing's Disease.
MERCADO-ASIS, L. B., Yasuda, K., Murayama, M. A., Mune, T., Morita, H., & Miura, K. (1992) · Endocrinologia Japonica · doi:10.1507/endocrj1954.39.385 · Cited by 37
Miyoshi, T., Otsuka, F., Takeda, M., Inagaki, K., Suzuki, J., Ogura, T., Date, I., Hashimoto, K., & Makino, H. (2004) · Journal of Endocrinological Investigation · doi:10.1007/bf03345309 · Cited by 29
Effect of injectable bromocriptine in patients with Cushing's disease
Invitti, C., Martin, M., Danesi, L., & Cavagnini, F. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1211361 · Cited by 23
Utilisation de la cabergoline dans la maladie de Cushing non contrôlée
Illouz, F., Dubois-Ginouves, S., Laboureau, S., Rohmer, V., & Rodien, P. (2006) · Annales d Endocrinologie · doi:10.1016/s0003-4266(06)72611-7 · Cited by 19
Boscaro, M., Zhang, Y., Sen, K., Maldonado, M., Schoenherr, U., & Jw, F. (2010) · The Endocrine Society's 92nd Annual Meeting, June 19–22, 2010 - San Diego · doi:10.1210/endo-meetings.2010.part1.p6.p1-274 · Cited by 9
Research works printed but not linked: 1
- 2007, Research in veterinary science, 85, 26
Cited by
Treatment of Cushing's syndrome: an Endocrine Society clinical practice guideline
Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1818 · Cited by 1,270
“Tumor volume decreased or remained stable in the small number of reported patients with visible adenomas (149, 150).”
BackgroundInfluentialConsensus on diagnosis and management of Cushing's disease: a guideline update
Fleseriu, M., Auchus, R., Bancos, I., Ben-Shlomo, A., Bertherat, J., Biermasz, N. R., Boguszewski, C. L., Bronstein, M. D., Buchfelder, M., Carmichael, J. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00235-7 · Cited by 953
“209,210 Of note, in reallife settings, few data are available about longterm treatment compliance, and several studies show a high rate of treatment discontinuation.”
Self-citationLacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Self-citationA 12-month phase 3 study of pasireotide in Cushing's disease
Colao, A., Petersenn, S., Newell-Price, J., Findling, J. W., Gu, F., Maldonado, M., Schoenherr, U., Dipl.-Biol., Mills, D., Salgado, L. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105743 · Cited by 628
“Fatigue 1 (1) 12 (15) 2 (2) 19 (24) 3 (2) 31 (19)”
The Treatment of Cushing's Disease
Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 465
Metadata
- Authors
- Godbout, A., Manavela, M., Danilowicz, K., Beauregard, H., Bruno, O. D., & Lacroix, A.
- Affiliations
- Centre Hospitalier de l’Université de Montréal (CA)
- Universidad de Buenos Aires (AR)
- Corresponding author
- Lacroix, André
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-11
- Volume
- 163
- Issue
- 5
- Pages
- 709-716
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2117410545
- Semantic Scholar
- f37fa26140b4922a437d18551ae1d042f3cb3beb
- Cited by
- 202
- References
- 35
- Citations by year
- 2026: 7 · 2025: 5 · 2024: 7 · 2023: 8 · 2022: 10 · 2021: 7 · 2020: 10 · 2019: 16 · 2018: 21 · 2017: 10 · 2016: 14 · 2015: 26 · 2014: 19 · 2013: 27 · 2012: 12
- FWCI
- 9.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Keywords
- cabergoline, Cushing's disease, dopamine agonists, long-term monotherapy, urinary free cortisol, treatment response, dose adjustment, pituitary ACTH-secreting tumor, corticotroph adenoma
- MeSH terms
- Cabergoline, Adult, Aged, Ergolines, Female, Follow-Up Studies, Humans, Hydrocortisone, Male, Middle Aged, Recurrence, Retrospective Studies, Time Factors, Cohort Studies, Pituitary ACTH Hypersecretion, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.